Tier 2 — strong

[Effects of berberine on the serum cystatin C levels and urine albumin/creatine ratio in patients with type 2 diabetes mellitus]

Li ZY, Liu B, Zhuang XJ, Shen YD, Tian HR, Ji Y, Li LX, Liu F
Zhonghua yi xue za zhi 2018 98(46):3756-3761

Bibliography

PubMed
PMID 30541217
DOI
10.3760/cma.j.issn.0376-2491.2018.46.007
Funding
Indexed support: Shanghai Jinshan Science and Technology Innovation Fund Program; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support. See the publication for grant details.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignRandomized controlled human trial
ModelHuman participants; see population
Sample114 adults with diabetes; 57 per arm
InterventionBerberine 400 mg three times/day added to glucose-lowering therapy versus usual therapy
Duration6 months
EndpointsUrine albumin/creatinine ratio; Serum cystatin C and eGFR; Glycemia and inflammatory measures

What the study showed, in plain terms

Albuminuria and cystatin-C measurements favored adjunctive treatment. These are renal surrogate measures.

Key findings

  • Albuminuria and cystatin-C measurements favored adjunctive treatment. These are renal surrogate measures.

What this study can and cannot tell us

A small, incompletely masked trial; not evidence of preventing dialysis, kidney failure or long-term decline.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Related papers in the corpus

Tier 2
The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial
Mansour A et al. · European journal of nutrition · 2025
Tier 2
Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes
Nikseresht M et al. · Physiological reports · 2024
Tier 2
Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial
Panigrahi A et al. · BMC endocrine disorders · 2023
Tier 2
Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial
Rondanelli M et al. · European review for medical and pharmacological sciences · 2023
Tier 2
Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection
Ruiz-Herrera VV et al. · International journal of STD & AIDS · 2023

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology